- Home
- CTRN vs CYBN Comparison
CTRN vs CYBN Comparison
Compare CTRN & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTRN | CYBN |
|---|---|---|
| Founded | 1946 | 2019 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 295.7M | 280.9M |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | CTRN | CYBN |
|---|---|---|
| Price | $44.19 | $5.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $52.00 | ★ $74.50 |
| AVG Volume (30 Days) | 112.4K | ★ 631.8K |
| Earning Date | 12-02-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $800,741,000.00 | N/A |
| Revenue This Year | $8.16 | N/A |
| Revenue Next Year | $5.38 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.77 | N/A |
| 52 Week Low | $16.82 | $4.81 |
| 52 Week High | $49.50 | $10.80 |
Technical Indicators
Market Signals| Indicator | CTRN | CYBN |
|---|---|---|
| Relative Strength Index (RSI) | 69.82 | 48.11 |
| Support Level | $37.85 | $5.50 |
| Resistance Level | $49.50 | $6.23 |
| Average True Range (ATR) | 2.86 | 0.33 |
| MACD | 0.13 | -0.02 |
| Stochastic Oscillator | 60.26 | 56.25 |
Price Performance
Historical ComparisonAbout CTRN Citi Trends Inc.
Citi Trends Inc is a retailer of urban fashion apparel and accessories in the United States. The company offers apparel, including fashion sportswear for men and women, as well as children, such as newborns, infants, toddlers, boys, and girls; accessories comprising handbags, jewelry, footwear, belts, intimate apparel, scrubs, and sleepwear; and functional and decorative home products, as well as beauty products, books and toys.
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.